NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free EDIT Stock Alerts $5.62 -0.27 (-4.58%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$5.59▼$5.9450-Day Range$5.04▼$9.1652-Week Range$4.91▼$11.91Volume1.74 million shsAverage Volume1.84 million shsMarket Capitalization$462.19 millionP/E RatioN/ADividend YieldN/APrice Target$13.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Editas Medicine alerts: Email Address Editas Medicine MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside147.3% Upside$13.90 Price TargetShort InterestBearish24.93% of Shares Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.74Based on 19 Articles This WeekInsider TradingSelling Shares$924,582 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.67) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.71 out of 5 starsMedical Sector274th out of 922 stocksBiological Products, Except Diagnostic Industry35th out of 155 stocks 3.3 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageEditas Medicine has only been the subject of 4 research reports in the past 90 days.Read more about Editas Medicine's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted24.93% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Editas Medicine has recently increased by 9.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 71.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.78. Previous Next 3.2 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Editas Medicine this week, compared to 4 articles on an average week.Search Interest25 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -21% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold 264.30% more of their company's stock than they have bought. Specifically, they have bought $253,800.00 in company stock and sold $924,582.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($2.67) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Editas Medicine's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaA ‘DeFi Summer’ Projected!Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x!Just click here to learn how you can access this coin right now. About Editas Medicine Stock (NASDAQ:EDIT)Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDIT Stock News HeadlinesMay 15 at 7:50 AM | insidertrades.comEditas Medicine, Inc. (NASDAQ:EDIT) Director Jessica Hopfield Acquires 45,000 SharesMay 16 at 7:04 AM | americanbankingnews.comJessica Hopfield Acquires 45,000 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) StockMay 16 at 2:16 AM | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 16 at 1:38 AM | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Shares Gap Up Following Insider Buying ActivityMay 15 at 5:50 PM | seekingalpha.comEditas Medicine: Promising Milestone Achieved But Be PatientMay 14 at 11:16 PM | finance.yahoo.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)May 14 at 10:00 AM | globenewswire.comEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in JuneMay 13, 2024 | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Forecasted to Post Q4 2024 Earnings of ($0.17) Per ShareMay 13, 2024 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) PT Lowered to $9.00 at BarclaysMay 13, 2024 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Upgraded to Equal Weight at Morgan StanleyMay 12, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 11, 2024 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Stock Rating Lowered by StockNews.comMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth PotentialMay 10, 2024 | markets.businessinsider.comEditas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal PrudenceMay 10, 2024 | globenewswire.comEditas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingMay 9, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | fool.com1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?May 9, 2024 | markets.businessinsider.comEditas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy RatingMay 9, 2024 | markets.businessinsider.comBuy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth OutlookMay 9, 2024 | finance.yahoo.comEditas Medicine First Quarter 2024 Earnings: Misses ExpectationsMay 8, 2024 | washingtonpost.comEditas: Q1 Earnings SnapshotMay 8, 2024 | investorplace.comEDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comEditas Medicine Announces First Quarter 2024 Results and Business UpdatesMay 7, 2024 | msn.comGene Editing Improves Vision in Rare and Devastating Retinal DisorderMay 7, 2024 | msn.comEditas Medicine Q1 2024 Earnings PreviewSee More Headlines Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/17/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees265Year FoundedN/APrice Target and Rating Average Stock Price Target$13.90 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+136.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,220,000.00 Net Margins-239.36% Pretax Margin-239.36% Return on Equity-47.34% Return on Assets-33.46% Debt Debt-to-Equity RatioN/A Current Ratio4.60 Quick Ratio4.60 Sales & Book Value Annual Sales$78.12 million Price / Sales6.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book1.65Miscellaneous Outstanding Shares82,240,000Free Float80,675,000Market Cap$484.39 million OptionableOptionable Beta2.09 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Gilmore O'Neill M.D. (Age 60)President, CEO & Director Comp: $1.04MMr. Erick J. Lucera C.F.A. (Age 56)CPA, CFO & Executive VP Comp: $911.46kDr. Linda C. Burkly Ph.D. (Age 67)Executive VP & Chief Scientific Officer Comp: $522.44kDr. Baisong Mei M.D. (Age 60)Ph.D., Executive VP & Chief Medical Officer Comp: $654.9kDr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 70)Co-Founder & Scientific Advisory Board Member More ExecutivesKey CompetitorsVoyager TherapeuticsNASDAQ:VYGRFate TherapeuticsNASDAQ:FATETaysha Gene TherapiesNASDAQ:TSHALexeo TherapeuticsNASDAQ:LXEOOcugenNASDAQ:OCGNView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 100 shares on 5/17/2024Ownership: 0.000%Kennedy Capital Management LLCBought 133,214 shares on 5/16/2024Ownership: 0.162%Jacobs Levy Equity Management Inc.Sold 165,688 shares on 5/16/2024Ownership: 0.145%California State Teachers Retirement SystemSold 4,591 shares on 5/16/2024Ownership: 0.090%Bayesian Capital Management LPBought 24,400 shares on 5/16/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions EDIT Stock Analysis - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EDIT shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price target for 2024? 10 brokers have issued 12 month target prices for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $20.00. On average, they predict the company's stock price to reach $13.90 in the next twelve months. This suggests a possible upside of 147.3% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2024? Editas Medicine's stock was trading at $10.13 at the start of the year. Since then, EDIT stock has decreased by 44.5% and is now trading at $5.62. View the best growth stocks for 2024 here. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.13. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $11.14 million. Editas Medicine had a negative net margin of 239.36% and a negative trailing twelve-month return on equity of 47.34%. The firm's quarterly revenue was down 88.9% on a year-over-year basis. During the same period last year, the firm posted ($0.71) earnings per share. What ETFs hold Editas Medicine's stock? ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Horizon Kinetics Medical ETF (MEDX), AXS Green Alpha ETF (NXTE) and Global X Genomics & Biotechnology ETF (GNOM).iShares Genomics Immunology and Healthcare ETF (IDNA). What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.40%), Mirae Asset Global Investments Co. Ltd. (0.38%), Susquehanna Portfolio Strategies LLC (0.22%), Los Angeles Capital Management LLC (0.18%), Kennedy Capital Management LLC (0.16%) and Jacobs Levy Equity Management Inc. (0.14%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Jessica Hopfield, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EDIT) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA ‘DeFi Summer’ Projected!Crypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceThe #1 Investment of the Decade… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
